Dataset Information


KIR2DL3 and KIR2DL1 show similar impact on licensing of human NK cells.

ABSTRACT: Killer cell immunoglobulin-like receptor/HLA class I (KIR/HLA-I) combinations are associated with disease risk, implicating functional roles for NK cells (NKCs) or KIR(+) T cells. KIR/HLA-I interactions can act through inhibition of NKC activation by target cells and NKC licensing for greater intrinsic responsiveness. We compared licensing conferred by the weaker, HLA-C group 1/KIR2DL3, and the stronger, HLA-C group 2/KIR2DL1, inhibitory combinations. The "rheostat model" predicts weaker licensing by HLA-C1/KIR2DL3 interactions than HLA-C2/KIR2DL1. We analyzed degranulation in NKC subsets expressing single and multiple receptors for HLA-I. NKG2A had the strongest licensing impact, while KIR2DL3, KIR2DL1, and KIR3DL1 were weaker, and not significantly different to each other. Presence of one or two matched HLA-C allotypes did not alter licensing of KIR2DL3(+) and KIR2DL1(+) NKC. Coexpression of activating KIR2DS1 disarmed KIR2DL3(+) and KIR2DL1(+) NKC to a similar extent. KIR3DL1 and NKG2A combined for more enhanced licensing of double-positive NKC than the combination of KIR2DL3 and KIR2DL1. Thus, KIR2DL3 and KIR2DL1 have similar capacity to license NKC, suggesting that inhibitory signal strength and amount of available HLA-C ligands do not correlate with NKC licensing. Altogether, our results show that the basis for disease associations of HLA-C and KIR2DL likely encompasses factors other than licensing.


PROVIDER: S-EPMC4737201 | BioStudies | 2016-01-01T00:00:00Z

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6916277 | BioStudies
2017-01-01 | S-EPMC5348643 | BioStudies
2019-01-01 | S-EPMC6929384 | BioStudies
2015-01-01 | S-EPMC4575877 | BioStudies
1000-01-01 | S-EPMC4506464 | BioStudies
2016-01-01 | S-EPMC5061331 | BioStudies
2016-01-01 | S-EPMC6684021 | BioStudies
1000-01-01 | S-EPMC2268583 | BioStudies
2009-01-01 | S-EPMC2774017 | BioStudies
2019-01-01 | S-EPMC7005656 | BioStudies